10-Q: Cidara's CD388 Flu Drug Shines in Phase 2b, Lands BARDA Funds

Cidara Therapeutics reports positive Phase 2b results for its lead influenza drug CD388, secures up to $339.2 million in BARDA funding, and initiates a Phase 3 trial, bolstering its financial runway despite continued net losses.

Summary

• Cidara Therapeutics reported a net loss of $83.2 million for the three months ended September 30, 2025, a significant increase from $16.0 million in the same period of 2024.
• For the nine months ended September 30, 2025, the net loss was $132.4 million, compared to $117.5 million for the prior year period.
• Research and development (R&D) expenses increased to $35.5 million for the three months ended September 30, 2025, up from $12.4 million in 2024, primarily due to CD388 manufacturing and Phase 3 ANCHOR study preparation.
• General and administrative (G&A) expenses rose to $8.1 million for the three months ended September 30, 2025, from $5.0 million in 2024, driven by higher personnel costs and legal fees.
• The company recognized $45.0 million in acquired in-process R&D expenses for the three and nine months ended September 30, 2025, related to a milestone payment for the ANCHOR study under the Janssen License Agreement.
• Cash, cash equivalents, restricted cash, and available-for-sale investments totaled $476.5 million as of September 30, 2025, a substantial increase from $196.2 million at December 31, 2024.
• This increase in liquidity was primarily due to $376.9 million in net proceeds from a June 2025 public offering and $4.1 million from an at-the-market offering.
• The accumulated deficit grew to $743.7 million as of September 30, 2025.
• A $9.4 million reversal due to the settlement of indirect tax liabilities was recorded for the nine months ended September 30, 2025, related to former rezafungin assets.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the strong clinical efficacy data for CD388, the significant regulatory designations (Fast Track and Breakthrough Therapy), and the substantial non-dilutive funding secured from BARDA. These factors significantly de-risk the lead asset and provide a clear path forward for its development. While the company continues to incur losses, the increased cash runway and strategic focus on a promising asset outweigh the short-term financial burn for a growth-oriented biotech.

Positives

• CD388's Phase 2b NAVIGATE study met its primary and all secondary efficacy endpoints, demonstrating 76.1%, 61.3%, and 57.7% protection from symptomatic influenza over 24 weeks for 450mg, 300mg, and 150mg doses, respectively, with a clear dose response and good tolerability.
• The FDA granted Breakthrough Therapy designation to CD388 in October 2025 for the prevention of influenza A and B in high-risk adults and adolescents, following its Fast Track designation in June 2023.
• Secured a BARDA Agreement on September 30, 2025, providing potential funding of up to $339.2 million, with an initial base period funding of $58.1 million over 24 months to support CD388 manufacturing onshoring and clinical development.
• Initiated the global Phase 3 ANCHOR study for CD388 in September 2025, six months ahead of the prior plan, with over 50% enrollment achieved by early November 2025.
• The ANCHOR study population has been expanded to include generally healthy adults over 65 and other high-risk groups, significantly increasing the potential patient base for CD388.
• The company's cash, cash equivalents, restricted cash, and available-for-sale investments increased significantly to $476.5 million, providing sufficient liquidity to fund operations through the completion of the Phase 3 development program.

Negatives

• The company continues to incur substantial operating losses, with a net loss of $83.2 million for the three months and $132.4 million for the nine months ended September 30, 2025.
• R&D expenses significantly increased by $23.1 million for the three months and $59.9 million for the nine months ended September 30, 2025, reflecting high development costs for CD388.
• General and administrative expenses also increased, contributing to the overall net loss.
• The company's accumulated deficit reached $743.7 million, indicating a history of unprofitability and expected future losses.
• Significant dilution of common stockholders' ownership interest occurred due to multiple equity offerings, with shares outstanding increasing from 10,946,635 at December 31, 2024, to 29,335,397 at September 30, 2025.

Risks

• Need for additional funding to advance CD388 beyond Phase 3 and other Cloudbreak programs, with no assurance of availability on acceptable terms or without stockholder approval.
• Heavy dependence on the success of CD388, with other Cloudbreak programs being in very early stages of development.
• Potential for delays, termination, or suspension of clinical trials for CD388 or other product candidates, or failure to demonstrate safety and efficacy, leading to increased costs or inability to complete development.
• Identification of serious adverse reactions or unexpected characteristics of product candidates during development could lead to abandonment or limitation of development.
• Failure of any approved product candidates to achieve sufficient market acceptance by physicians, patients, formulary committees, and third-party payors for commercial success.
• Interim, topline, and preliminary clinical trial data may change upon comprehensive review, potentially altering final results or conclusions.
• Reliance on third parties to conduct clinical trials, research, and preclinical testing, with risks of unsatisfactory performance or failure to meet deadlines.
• Lack of experience in manufacturing product candidates on a clinical or commercial scale and dependence on third-party manufacturers, including those in China (e.g., WuXi XDC), posing risks of delays, quality issues, and supply chain disruptions.
• Inability to obtain or delays in obtaining required regulatory approvals, impairing commercialization and revenue generation.
• Volatility in the company's stock price, potentially leading to loss of investment.
• Potential for dilution of stockholders' ownership from future equity or convertible debt financings.
• Exposure to unfavorable global economic conditions, including inflation, high interest rates, bank failures, and geopolitical conflicts, which could affect funding and operations.
• Adverse impacts from international trade policies, including tariffs, sanctions, and trade barriers (e.g., BIOSECURE Act targeting Chinese biotechnology companies), particularly affecting manufacturing and supply chain.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Non-compliance with environmental, health, and safety laws and regulations could lead to fines or penalties.
• Challenges in establishing collaborations or obtaining government grants on commercially reasonable terms.
• Risks related to U.S. government contracts and grants, including termination rights, intellectual property claims, audits, and compliance requirements.
• Vulnerability of information technology systems and data to compromise, leading to regulatory investigations, litigation, and business disruptions.
• Compliance with stringent and evolving U.S. and foreign data privacy and security laws, regulations, and rules, with potential for significant penalties for non-compliance.
• Uncertainties in the interpretation and application of existing, new, and proposed tax laws and regulations (e.g., OBBBA, IRA, Bayh-Dole Act march-in rights) could affect tax obligations and effective tax rate.
• Vulnerability of operations to interruption by natural disasters, power loss, terrorist activity, and public health crises.

Future Outlook

The company expects to continue incurring net losses into the foreseeable future as it advances CD388 through its Phase 3 development program. It believes its current liquidity of $476.5 million is sufficient to fund operations through the completion of this program. The BARDA Agreement provides significant potential funding to support CD388 manufacturing onshoring and additional clinical/non-clinical studies, complementing the company's plans for a potential Biologics License Application (BLA) submission to the FDA. The company plans to initiate a Phase 1 vaccine interaction study and a Phase 2 repeat dose study for CD388 in mid-November 2025.

Management Comments

• We believe our proprietary Cloudbreak platform has the potential to offer a fundamentally new approach to treat and prevent serious diseases such as viral infections and solid tumors cancers.
• We believe CD388 has the potential to provide universal protection against all influenza A and B virus strains, including high pathogenicity strains like H5N1, with potential for single dose per flu season protection.
• We believe our existing cash, cash equivalents, restricted cash and available-for-sale investments will be sufficient to fund our planned operations through the completion of our Phase 3 development program.

Industry Context

Cidara Therapeutics operates in the highly competitive biotechnology sector, specifically targeting infectious diseases and oncology with its novel Drug-Fc Conjugate (DFC) Cloudbreak platform. The positive Phase 2b results for CD388 position it as a promising long-acting antiviral in the influenza market, which is characterized by existing vaccines (traditional and mRNA-based), monoclonal antibodies, and small molecule neuraminidase inhibitors. The FDA's Fast Track and Breakthrough Therapy designations highlight the significant unmet medical need for improved influenza prevention, particularly in high-risk populations. The BARDA funding underscores government interest in pandemic preparedness and novel antiviral solutions, providing a strategic advantage in a market often driven by public health initiatives. The company's focus on DFCs differentiates it from traditional antibody-drug conjugates (ADCs) and monoclonal antibodies, aiming for better tissue penetration and multi-site targeting.

Management Changes

Corporate Governance

Related Party Transactions

• Janssen Pharmaceuticals, Inc.: Reacquired all rights for CD388 from Janssen under a license and technology transfer agreement on April 23, 2024, for an upfront payment of $85.0 million. The company is obligated to pay Janssen up to $150.0 million in development and regulatory milestone payments and up to $455.0 million in commercialization milestone payments for CD388. A $45.0 million milestone was incurred in September 2025 upon dosing the first five subjects in the ANCHOR study.
• Napp Pharmaceutical Group Limited (an affiliate of Mundipharma Medical Company): Sold all rezafungin assets and related contracts to Napp on April 24, 2024. This included the right to receive future milestones and royalties from Melinta Therapeutics, LLC and Mundipharma Medical Company. Mundipharma also forgave an $11.1 million development milestone advance as part of this transaction.

Stakeholder Impact

• Shareholders: Experienced significant dilution from recent equity offerings but benefit from a strengthened cash position and positive clinical/regulatory progress for the lead asset, potentially increasing long-term value.
• Patients: Potential for a new, long-lasting antiviral treatment for seasonal and pandemic influenza, especially for high-risk populations, improving standard of care.
• Employees: Workforce reduction in September 2024 indicates a strategic shift and focus, potentially impacting morale but aligning resources with core objectives.
• Government (BARDA): Partnership with BARDA demonstrates a commitment to public health preparedness and provides substantial funding for CD388's development and U.S. manufacturing capabilities.
• Partners (Janssen, Napp/Mundipharma): Restructured relationships, with Janssen now a milestone recipient for CD388 and Napp/Mundipharma taking over rezafungin assets.

Next Steps

• Complete enrollment of 6,000 participants in the Phase 3 ANCHOR study by December 2025.
• Conduct an interim analysis for the ANCHOR study in the first quarter of 2026 to assess trial size and powering assumptions.
• Initiate a Phase 1 vaccine interaction study and a Phase 2 repeat dose study of CD388 in mid-November 2025.
• Continue non-clinical testing to evaluate CD388's effectiveness against current and emerging influenza viruses with pandemic potential.
• Establish a robust and secure domestic manufacturing infrastructure for CD388 by transferring production processes to a U.S.-based CDMO.
• Perform a bridging Safety/PK clinical trial to support a higher concentration formulation of CD388.
• Develop clinical trial protocols for expanded populations for CD388.
• Pursue potential Biologics License Application (BLA) approval for CD388 based on successful ANCHOR study results.

Key Dates

Recommendation

The company has achieved significant de-risking milestones for its lead asset, CD388, including positive Phase 2b clinical trial results, FDA Breakthrough Therapy designation, and substantial non-dilutive funding from BARDA. These developments provide a strong foundation for the ongoing Phase 3 trial and potential future commercialization. While the company is still pre-revenue and incurring losses, the strengthened cash position provides a solid runway, and the strategic focus on a high-potential asset in a critical therapeutic area (influenza prevention) presents a compelling long-term investment opportunity for investors with a higher risk tolerance in the biotechnology sector.

Keywords

Biotechnology, Influenza, Antiviral, CD388, Cloudbreak platform, Drug-Fc conjugate, DFC, Phase 2b clinical trial, NAVIGATE study, Phase 3 clinical trial, ANCHOR study, FDA Fast Track designation, FDA Breakthrough Therapy designation, BARDA funding, SEC filing, Biologics License Application, BLA, Clinical development, Biopharmaceutical, Infectious diseases